US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global rights to a preclinical asset. Under the deal, Candid ...

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics ... expedite the process by 6-18 months and ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925 million biobucks deal with WuXi Biologics for a preclinical candidate.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We’re glad to enable Candid to advance the progress of T-cell engagers through WuXiBody TM. This collaboration not only showcases the platform ...

Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced ...

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal ... expedite the process by 6 ...